CTSO - Cytosorbents Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Cytosorbents Corporation

7 Deer Park Drive
Suite K
Monmouth Junction, NJ 08852
United States
732-329-8885
http://www.cytosorbents.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees101

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip P. ChanCEO, Pres & Director350kN/A1970
Ms. Kathleen P. Bloch MBA, CPACFO & Sec.255kN/A1955
Mr. Vincent J. Capponi MSChief Operating Officer291kN/A1958
Dr. Eric R. MortensenChief Medical OfficerN/AN/A1959
Dr. Robert H. BartlettCo-Chairman of Cardiac Surgery Advisory Board & Consultant54kN/A1939
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.

Corporate Governance

Cytosorbents Corporation’s ISS Governance QualityScore as of October 1, 2018 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.